Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim
Can Recursion accelerate the time frame for drug discovery? Last year, Recursion announced that tech giant Nvidia invested $50 million into its operations. Together, the businesses are working on drug ...
Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...
The deal to merge into Recursion caps off a tumultuous year for Exscientia, which uses AI to aid drug discovery. (asbe/iStock/Getty Images Plus) After a year defined by pipeline cuts, the departure of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results